

**EUROPEAN
CURRICULUM VITAE
FORMAT**



PERSONAL INFORMATION

Name	FEDERICO PIACENTINI
Address	Department of Medical and Surgical Sciences for Children & Adults Division of Medical Oncology AOU Policlinico di Modena - Centro Oncologico Modenese University of Modena and Reggio Emilia Via del Pozzo, 71 41125 Modena – Italy
Telephone	+ 39-059-4222661
Fax	+ 39-059-4224429
E-mail	federico.piacentini@unimore.it
Nationality	Italian
Date and place of birth	January 4, 1979, Carpi (Modena), Italy

WORK EXPERIENCE

- Dates (from – to) 11/2022 - present
- Name and address of the employer Division of Medical Oncology,
Modena University Hospital, Modena, Italy
- Occupation or position held Associate Professor
- Dates (from – to) 12/2010 – 10/2022
- Name and address of the employer Division of Medical Oncology,
Modena University Hospital, Modena, Italy
- Occupation or position held Assistant Professor
- Dates (from – to) 2008-2010
- Name and address of the employer Division of Oncology
Modena University Hospital, Modena, Italy
- Occupation or position held Attending Physician
- Dates (from – to) 2005-2008
- Name and address of the employer Modena University Hospital, Modena, Italy
- Occupation or position held Post-graduate Specialization in Medical Oncology

**ACADEMIC POSITION
WORK EXPERIENCE**

- Dates (from – to) 11/2022 - onwards

- Name and address of the employer
Division of Medical Oncology,
Modena University Hospital, Modena, Italy
- Occupation or position held
Associate Professor
- Dates (from - to)
12/2010 – 10/2022
- Name and type of organization
Modena and Reggio Emilia School of Medicine, Modena, Italy
- Principal subjects/occupational skills covered
Clinical Oncology
- Title of qualification awarded
Assistant Professor

EDUCATION AND TRAINING

- Dates
2008-2010
- Name and type of organization providing education and training
University of Modena and Reggio Emilia, Modena, Italy
- Principal subjects/occupational skills covered
Different adjuvant chemotherapy plus trastuzumab in HER2 positive breast cancer patients
- Title of qualification awarded
Fellowship
- Dates
2005-2008
- Name and type of organization providing education and training
University of Modena and Reggio Emilia, Modena, Italy
- Title of qualification awarded
Specialty in Medical Oncology, graduated 110/110 cum laude
- Date
09 march 2005
- Title of qualification awarded
Italian Medical Licensure number 5904 at 'ORDINE PROVINCIALE DEI MEDICI CHIRURGHI E DEGLI ODONTOIATRI DI MODENA', Modena, Italy
- Dates
1997-2004
- Name and type of organization providing education and training
University of Modena and Reggio Emilia, Modena, Italy
- Title of qualification awarded
M.D. degree 110/110
- Date
1997
- Name and type of organization providing education and training
Liceo Scientifico Manfredo Fanti, Carpi (MO), Italy
- Title of qualification awarded
Scientific Bachelor Degree 60/60

MOTHER TONGUE

Italian

OTHER LANGUAGES

English

- Reading skills
EXCELLENT
- Writing skills
GOOD
- Verbal skills
GOOD

ANNEXES

Research
Scientific Affiliations
Scientific Publications

Research

Participation as Principal Investigator or Co-Investigator in more than 40 clinical trials phase 2 to 4, mainly concerning Breast Cancer disease, since 2006

Scientific Affiliation

- Italian Association Medical Oncology (AIOM)

Publications:

Dr. Piacentini is author or co-author of 90 papers published on peer-reviewed Journals:

1. CARCINOMA RENALE: STATO DELL'ARTE E NUOVI FARMACI.
Sabbatini R, Maur M, Ferrari A, Piacentini F, Giovannelli S, Conte PF.
Boll Soc Med Chir Modena. 2005; 4-6: 15-22
2. PREOPERATIVE CHEMOTHERAPY PLUS LAPATINIB OR TRASTUZUMAB OR BOTH IN HER2-POSITIVE OPERABLE BREAST CANCER (CHERLOB TRIAL).
Guarneri V, Frassoldati A, Piacentini F, Jovic G, Giovannelli S, Oliva C, Conte P.
Clin Breast Cancer. 2008 Apr;8(2):192-4
3. DEVELOPMENT OF HYPOGAMMAGLOBULINEMIA IN CHRONIC MYELOID LEUKEMIA AND GASTROINTESTINAL STROMAL TUMOR PATIENTS TREATED WITH IMATINIB.
Santachiara R, Maffei R, Martinelli S, Arcari A, Piacentini F, Elena T, Alfieri P, Ferrari A, Leonardi G, Luppi G, Longo G, Vallisa D, Marasca R, Torelli G.
Haematologica. 2008 Jun 2
4. PHASE II, RANDOMIZED TRIAL OF PREOPERATIVE EPIRUBICIN-PACLITAXEL +/- GEFITINIB WITH BIOMARKER EVALUATION IN OPERABLE BREAST CANCER
Guarneri V, Frassoldati A, Ficarra G, Puglisi F, Andreetta C, Michelotti A, Cresti N, Boni C, Bisagni G, Berardi R, Battelli N, Santoro A, Banna G, Bottini A, Blasio BD, Maiorana A, Piacentini F, Giovannelli S, Jovic G, Conte P.
Breast Cancer Res Treat. 2008 Jul;110(1):127-34
5. LETROZOLE VERSUS LETROZOLE PLUS LAPATINIB (GW572016) IN HORMONE-SENSITIVE, HER2-NEGATIVE OPERABLE BREAST CANCER: A DOUBLE-BLIND, RANDOMIZED, PHASE II STUDY WITH BIOMARKER EVALUATION (EGF109077-LAP107692/LETLOB).
Frassoldati A, Guarneri V, Piacentini F, Jovic G, Giovannelli S, Oliva C, Conte PF.
Clin Breast Cancer. 2008 Feb;8(1):97-100
6. COMPARISON OF HER-2 AND HORMONE RECEPTOR EXPRESSION IN PRIMARY BREAST CANCERS AND ASYNCHRONOUS PAIRED METASTASES: IMPACT ON PATIENT MANAGEMENT.
Guarneri V, Giovannelli S, Ficarra G, Bettelli S, Maiorana A, Piacentini F, Barbieri E, Dieci MV, D'Amico R, Jovic G, Conte P.
Oncologist. 2008 Aug;13(8):838-44. 2008 Jul 23
7. A PROGNOSTIC MODEL BASED ON NODAL STATUS AND KI-67 PREDICTS THE RISK OF RECURRENCE AND DEATH IN BREAST CANCER PATIENTS WITH RESIDUAL DISEASE AFTER PREOPERATIVE CHEMOTHERAPY.
Guarneri V, Piacentini F, Ficarra G, Frassoldati A, D'Amico R, Giovannelli S, Maiorana A, Jovic G, Conte P.
Ann Oncol. 2009 Jul;20(7):1193-8
8. ACHIEVEMENTS AND UNMET NEEDS IN THE MANAGEMENT OF ADVANCED OVARIAN CANCER
Guarneri V, Piacentini F, Barbieri E, Conte PF
Gynecol Oncol. 2010 Jan; 5 117(2):152-8
9. PREDICTIVE AND PROGNOSTIC ROLE OF P53 ACCORDING TO TUMOR PHENOTYPE IN BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY: A SINGLE INSTITUTION ANALYSIS
Guarneri V, Barbieri E, Piacentini F, Giovannelli S, Ficarra G, Frassoldati A, Maiorana A, D'Amico R, Conte PF
Int J Biol Markers. 2010 May 31
10. ANTI-HER2 NEOADJUVANT AND ADJUVANT THERAPIES IN HER2 POSITIVE BREAST CANCER

Guarneri V, Barbieri E, Dieci MV, Piacentini F, Conte PF
Cancer Treat Rev. 2010 Nov; 36S3: S62-S66

11. TIMING FOR STARTING SECOND-LINE THERAPY IN RECURRENT OVARIAN CANCER.

Guarneri V, Barbieri E, Dieci MV, Piacentini F, Conte P.
Expert Rev Anticancer Ther. 2011 Jan;11(1):49-55

12. MAGNETIC RESONANCE IMAGING AND ULTRASONOGRAPHY IN PREDICTING INFILTRATING RESIDUAL DISEASE AFTER PREOPERATIVE CHEMOTHERAPY IN STAGE II-III BREAST CANCER

Guarneri V, Pecchi A, Piacentini F, Barbieri E, Dieci MV, Ficarra G, Tazzioli G, Frassoldati A, Battista R, Canossi B, Mauri C, D'Amico R, Conte P, Torricelli P.
Ann Surg Oncol. 2011 Feb 8

13. PRIMARY PULMONARY CANCER COLLIDING WITH METASTATIC BREAST CARCINOMA: HITHERTO UNREPORTED CASES OF CANCER-TO-CANCER METASTASIS FOCUSING ON CLINICAL IMPLICATIONS.

Piacentini F, Rossi G, Casali C, Cadioli A, Barbieri E, Guarneri V.
Lung Cancer. 2011 Oct;74(1):145-8

14. PREDICTORS OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 FLUORESCENCE IN-SITU HYBRIDISATION AMPLIFICATION IN IMMUNOHISTOCHEMISTRY SCORE 2+ INFILTRATING BREAST CANCER: A SINGLE INSTITUTION ANALYSIS.

Dieci MV, Barbieri E, Bettelli S, Piacentini F, Omarini C, Ficarra G, Balduzzi S, Dominici M, Conte P, Guarneri V.
J Clin Pathol. 2012 Mar 3

15. PREOPERATIVE CHEMOTHERAPY PLUS TRASTUZUMAB, LAPATINIB, OR BOTH IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE OPERABLE BREAST CANCER: RESULTS OF THE RANDOMIZED PHASE II CHER-LOB STUDY.

Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, Ravaioli A, Cavanna L, Giardina G, Musolino A, Untch M, Orlando L, Artioli F, Boni C, Generali DG, Serra P, Bagnalasta M, Marini L, Piacentini F, D'Amico R, Conte P
J Clin Oncol. 2012 Apr 9

16. DISCORDANCE IN RECEPTOR STATUS BETWEEN PRIMARY AND RECURRENT BREAST CANCER HAS A PROGNOSTIC IMPACT: A SINGLE-INSTITUTION ANALYSIS.

Dieci MV, Barbieri E, Piacentini F, Ficarra G, Bettelli S, Dominici M, Conte PF, Guarneri V
Ann Oncol. 2013 Jan;24(1):101-8

17. LOSS OF HER2 POSITIVITY AND PROGNOSIS AFTER NEOADJUVANT THERAPY IN HER2-POSITIVE BREAST CANCER PATIENTS.

Guarneri V, Dieci MV, Barbieri E, Piacentini F, Omarini C, Ficarra G, Bettelli S, Conte PF.
Ann Oncol. 2013 Sep 7

18. DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, RANDOMIZED, PHASE IIB NEOADJUVANT STUDY OF LETROZOLE-LAPATINIB IN POSTMENOPAUSAL HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE, OPERABLE BREAST CANCER.

Guarneri V, Generali DG, Frassoldati A, Artioli F, Boni C, Cavanna L, Tagliafico E, Maiorana A, Bottini A, Cagossi K, Bisagni G, Piacentini F, Ficarra G, Bettelli S, Roncaglia E, Nuzzo S, Swaby R, Ellis C, Holford C, Conte P
J Clin Oncol. 2014 Apr 1;32(10):1050-7

19. QUANTITATIVE EXPRESSION OF ESTROGEN RECEPTOR ON RELAPSE BIOPSY FOR ER-POSITIVE BREAST CANCER: PROGNOSTIC IMPACT.

Dieci MV, Piacentini F, Dominici M, Omarini C, Goubar A, Ficarra G, Conte P, Guarneri V.
Anticancer Res. 2014 Jul;34(7):3657-62

20. PREOPERATIVE CARBOPLATIN-PACLITAXEL-BEVACIZUMAB IN TRIPLE-NEGATIVE BREAST CANCER: FINAL RESULTS OF THE PHASE II CA.PA.BE STUDY.

Guarneri V, Dieci MV, Bisagni G, Boni C, Cagossi K, Puglisi F, Pecchi A, Piacentini F, Conte P.
Ann Surg Oncol. 2015 Jan 9.

21. PROGNOSTIC FACTORS FOR BREAST CANCER: AN IMMUNOMORPHOLOGICAL UPDATE

Roncati L, Barbolini G, Piacentini F, Pisciolli f, Pusioli T, Maiorana A
Pathol Oncol Res 2015 Nov 20

22. AFATINIB ALONE OR AFATINIB PLUS VINOURELBINE VERSUS INVESTIGATOR'S CHOICE OF TREATMENT FOR HER2-POSITIVE BREAST CANCER WITH PROGRESSIVE BRAIN METASTASES AFTER TRASTUZUMAB, LAPATINIB, OR BOTH (LUX-BREAST 3): A RANDOMISED, OPEN-LABEL, MULTICENTRE, PHASE 2 TRIAL
Cortés J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, Le Rhun E, Espié M, Kim SB, Schneeweiss A, Sohn JH, Nabholz JM, Kellokumpu-Lehtinen PL, Taguchi J, Piacentini F, Ciruelos E, Bono P, Ould-Kaci M, Roux F, Joensuu H
Lancet Oncol 2015
23. PROGNOSTIC FACTORS FOR BREAST CANCER: AN IMMUNOMORPHOLOGICAL UPDATE.
Roncati L, Barbolini G, Piacentini F, Pisciole F, Pusiol T, Maiorana A.
Pathol Oncol Res. 2016 Jul;22(3):449-52
24. TUMOR STROMA MANIPULATION BY MSC.
Grisendi G, Spano C, Rossignoli F, D'souza N, Golinelli G, Fiori A, Horwitz EM, Guarneri V, Piacentini F, Paolucci P, Dominici M.
Curr Drug Targets. 2016 Mar 7
25. IMMUNOGLOBULIN G FRAGMENT C RECEPTOR POLYMORPHISMS AND EFFICACY OF PREOPERATIVE CHEMOTHERAPY PLUS TRASTUZUMAB AND LAPATINIB IN HER2-POSITIVE BREAST CANCER.
Musolino A, Naldi N, Dieci MV, Zanoni D, Rimanti A, Boggiani D, Sgargi P, Generali DG, Piacentini F, Ambroggi M, Cagossi K, Gianni L, Sarti S, Bisagni G, Ardizzoni A, Conte PF, Guarneri V.
Pharmacogenomics J. 2016 Jul 5
26. INTEGRATED EVALUATION OF PAM50 SUBTYPES AND IMMUNE MODULATION OF PCR IN HER2-POSITIVE BREAST CANCER PATIENTS TREATED WITH CHEMOTHERAPY AND HER2-TARGETED AGENTS IN THE CHERLOB TRIAL.
Dieci MV, Prat A, Tagliafico E, Paré L, Ficarra G, Bisagni G, Piacentini F, Generali DG, Conte P, Guarneri V.
Ann Oncol. 2016 Oct;27(10):1867-73
27. IMPACT OF TIME TO SURGERY AFTER NEOADJUVANT CHEMOTHERAPY IN OPERABLE BREAST CANCER PATIENTS.
Omarini C, Guaitoli G, Noventa S, Andreotti A, Gambini A, Palma E, Papi S, Tazzioli G, Balduzzi S, Dominici M, Cascinu S, Piacentini F.
Eur J Surg Oncol. 2016 Oct 20
28. MOLECULAR BIOMARKERS FOR PREDICTION OF TARGETED THERAPY RESPONSE IN METASTATIC BREAST CANCER: TRICK OR TREAT?
Toss A, Venturelli M, Peterle C, Piacentini F, Cascinu S, Cortesi L.
Int J Mol Sci. 2017 Jan 4;18(1)
29. METRONOMIC CAPECITABINE EFFECTIVELY BLOCKS LEPTOMENINGEAL CARCINOMATOSIS FROM BREAST CANCER: A CASE REPORT AND LITERATURE REVIEW.
Maur M, Omarini C, Piacentini F, Fontana A, Pettorelli E, Cascinu S.
Am J Case Rep. 2017 Feb 28;18:208-211
30. TUMOR-INFILTRATING LYMPHOCYTES AND MOLECULAR RESPONSE AFTER NEOADJUVANT THERAPY FOR HR+/HER2- BREAST CANCER: RESULTS FROM TWO PROSPECTIVE TRIALS.
Dieci MV, Frassoldati A, Generali D, Bisagni G, Piacentini F, Cavanna L, Cagossi K, Puglisi F, Michelotti A, Berardi R, Banna G, Goubar A, Ficarra G, Griguolo G, Conte P, Guarneri V.
Breast Cancer Res Treat. 2017 Jun;163(2):295-302
31. OSTEONECROSIS OF THE JAW IN A BREAST CANCER PATIENT TREATED WITH EVEROLIMUS AND A SINGLE DOSE OF ZOLEDRONIC ACID.
Omarini C, Filieri ME, Depenni R, Grizzi G, Cascinu S, Piacentini F.
Breast J. 2017 Mar 22
32. GD2 EXPRESSION IN BREAST CANCER.
Orsi G, Barbolini M, Ficarra G, Tazzioli G, Manni P, Petrachi T, Mastrolia I, Orvieto E, Spano C, Prapa M, Kaleci S, D'Amico R, Guarneri V, Dieci MV, Cascinu S, Conte P, Piacentini F, Dominici M.
Oncotarget. 2017 May 9;8(19):31592-31600

33. EVEROLIMUS PLUS EXEMESTANE IN ADVANCED BREAST CANCER: SAFETY RESULTS OF THE BALLET STUDY ON PATIENTS PREVIOUSLY TREATED WITHOUT AND WITH CHEMOTHERAPY IN THE METASTATIC SETTING.
Generali D, Montemurro F, Bordonaro R, Mafodda A, Romito S, Michelotti A, Piovano P, Ionta MT, Bighin C, Sartori D, Frassoldati A, Cazzaniga ME, Riccardi F, Testore F, Vici P, Barone CA, Schirone A, Piacentini F, Nolè F, Molino A, Latini L, Simoncini EL, Roila F, Cognetti F, Nuzzo F, Foglietta J, Minisini AM, Goffredo F, Portera G, Ascione G, Mariani G.
Oncologist. 2017 Jun;22(6):648-654
34. A RETROSPECTIVE MULTICENTRIC OBSERVATIONAL STUDY OF TRASTUZUMAB EMTANSINE IN HER2 POSITIVE METASTATIC BREAST CANCER: A REAL-WORLD EXPERIENCE. Vici P, Pizzuti L, Michelotti A, Sperduti I, Natoli C, Mentuccia L, Di Lauro L, Sergi D, Marchetti P, Santini D, Magnolfi E, Iezzi L, Moscetti L, Fabbri A, Cassano A, Grassadonia A, Omarini C, Piacentini F, Botticelli A, Bertolini I, Scinto AF, Zampa G, Mauri M, D'Onofrio L, Sini V, Barba M, Maugeri-Saccà M, Rossi E, Landucci E, Tomao S, Alberti AM, Giotta F, Ficorella C, Adamo V, Russo A, Lorusso V, Cannita K, Barni S, Laudadio L, Greco F, Garrone O, Giulia MD, Marolla P, Sanguineti G, Di Cocco B, Ciliberto G, De Maria R, Gamucci T.
Oncotarget. 2017 May 25
35. NEOADJUVANT TREATMENTS IN TRIPLE-NEGATIVE BREAST CANCER PATIENTS: WHERE WE ARE NOW AND WHERE WE ARE GOING
Omarini C, Guaitoli G, Pipitone S, Moscetti L, Cortesi L, Cascinu S, Piacentini F.
Cancer Management and Research 2018;10 91–103
36. IMMUNE CHARACTERIZATION OF BREAST CANCER METASTASES: PROGNOSTIC IMPLICATIONS.
Dieci MV, Tsvetkova V, Orvieto E, Piacentini F, Ficarra G, Griguolo G, Miglietta F, Giarratano T, Omarini C, Bonaguro S, Cappellesso R, Aliberti C, Vernaci G, Giorgi CA, Faggioni G, Tasca G, Conte P, Guarneri V.
Breast Cancer Res. 2018 Jun 22;20(1):62
37. MUTATIONAL PROFILE OF METASTATIC BREAST CANCER TISSUE IN PATIENTS TREATED WITH EXEMESTANE PLUS EVEROLIMUS
Claudia Omarini , Maria Elisabetta Filieri, Stefania Bettelli, Samantha Manfredini, Shaniko Kaleci, Cecilia Caprera, Cecilia Nasso, Monica Barbolini, Giorgia Guaitoli, LucaMoscetti, Antonino Maiorana, Pier Franco Conte, Stefano Cascinu, and Federico Piacentini
BioMed Research International Volume 2018, Article ID 3756981, 8 pages <https://doi.org/10.1155/2018/3756981>
38. CLINICAL AND MOLECULAR PREDICTORS OF LONG-TERM RESPONSE IN HER2 POSITIVE METASTATIC BREAST CANCER PATIENTS
Claudia Omarini, Stefania Bettelli, Cecilia Caprera, Samantha Manfredini, Federica Caggia, Giorgia Guaitoli, Luca Moscetti, Angela Toss, Laura Cortesi, Shaniko Kaleci, Antonino Maiorana, Stefano Cascinu, Pier Franco Conte & Federico Piacentini
Cancer Biol Ther. 2018 Aug 1:1-8
39. 9 WEEKS VS 1 YEAR ADJUVANT TRASTUZUMAB IN COMBINATION WITH CHEMOTHERAPY: FINAL RESULTS OF THE PHASE III RANDOMIZED SHORT-HER STUDY. Conte P, Frassoldati A, Bisagni G, Brandes AA, Donadio M, Garrone O, Piacentini F, Cavanna L, Giotta F, Aieta M, Gebbia V, Molino A, Musolino A, Ferro A, Maltoni R, Danese S, Zamagni C, Rimanti A, Cagossi K, Russo A, Pronzato P, Giovanardi F, Moretti G, Lombardo L, Schirone A, Beano A, Amaducci L, Bajardi EA, Vicini R, Balduzzi S, D'Amico R, Guarneri V.
Ann Oncol. 2018 Sep 13
40. POST-SURGICAL PYODERMA GANGRENOSUM OF THE BREAST: NEEDS FOR EARLY DIAGNOSIS AND RIGHT THERAPY.
Guaitoli G, Piacentini F, Omarini C, Andreotti A, Palma E, Papi S, De Pietri C, Conti A, Cascinu S, Tazzioli G.
Breast Cancer. 2018 Dec 18.
41. BREAST LOCATION FOR DE NOVO EXTRAMEDULLARY MYELOID SARCOMA
Giovanni Tazzioli, Enza Palma, Anna Gambini, Andrea Messerotti, Leonardo Potenza, Mario Luppi, Antonella Drago, Maria Grazia Amorico, Monica Barbolini, Guido Ficarra and Federico Piacentini
Clin Oncol. 2018; 3: 1525.
42. PHASE II STUDY OF DEHYDROEPIANDROSTERONE IN ANDROGEN RECEPTOR-POSITIVE METASTATIC BREAST CANCER
Pietri E, Massa I, Bravaccini S, Ravaoli S, Tumedei MM, Petracci E, Donati C, Schirone A, Piacentini F, Gianni L, Nicolini M, Campadelli E, Gennari A, Saba A, Campi B, Valmorri L, Andreis D, Fabbri F, Amadori D, Rocca A.

43. DIFFERENTIAL MOLECULAR PATHWAYS EXPRESSION IN HER2 POSITIVE EARLY BREAST CANCER ACCORDING TO HORMONE RECEPTOR STATUS.

Omarini C, Bettelli S, Caprera C, Manfredini S, Barbolini M, Moscetti L, Isca C, Toss A, Barbieri E, Cortesi L, Kaleci S, Maiorana A, Tazzioli G, Cascinu S, Piacentini F.
J Cancer Res Clin Oncol. 2019 Jan

44. FIRST-LINE TREATMENT FOR ENDOCRINE-SENSITIVE BONE-ONLY METASTATIC BREAST CANCER: SYSTEMATIC REVIEW AND META-ANALYSIS.

Toss A, Venturelli M, Sperduti I, Molinaro E, Isca C, Barbieri E, Piacentini F, Omarini C, Cortesi L, Cascinu S, Moscetti L.
Clin Breast Cancer. 2019 Jul 24.

45. ASSOCIATION OF TUMOR-INFILTRATING LYMPHOCYTES WITH DISTANT DISEASE-FREE SURVIVAL IN THE SHORTER RANDOMIZED ADJUVANT TRIAL FOR PATIENTS WITH EARLY HER2+ BREAST CANCER.

Dieci MV, Conte P, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Musolino A, Giotta F, Rimanti A, Garrone O, Bertone E, Cagossi K, Sarti S, Ferro A, Piacentini F, Maiorana A, Orvieto E, Sanders M, Miglietta F, Balduzzi S, D'Amico R, Guarneri V.
Ann Oncol. 2019 Mar 1;30(3):418-423.

46. DISTINCT HR EXPRESSION PATTERNS SIGNIFICANTLY AFFECT THE CLINICAL BEHAVIOR OF METASTATIC HER2+ BREAST CANCER AND DEGREE OF BENEFIT FROM NOVEL ANTI-HER2 AGENTS IN THE REAL WORLD SETTING.

Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, Izzo F, Sanguineti G, Marchetti P, Mazzotta M, Giusti R, Botticelli A, Gamucci T, Natoli C, Grassadonia A, Tinari N, Iezzi L, Tomao S, Tomao F, Tonini G, Santini D, Astone A, Michelotti A, De Angelis C, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Rossi E, Cazzaniga M, Moscetti L, Omarini C, Piacentini F, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Samaritani R, Garufi C, Barni S, Mirabelli R, Sarmiento R, Veltri EM, D'Auria G, Paris I, Giotta F, Lorusso V, Cardillo F, Landucci E, Mauri M, Ficorella C, Roselli M, Adamo V, Ricciardi GRR, Russo A, Berardi R, Pistelli M, Fiorio E, Cannita K, Sini V, D'Ostilio N, Foglietta J, Greco F, Zamagni C, Garrone O, Di Cocco B, Baldini E, Livi L, Desideri I, Meattini I, Sarobba G, Del Medico P, De Tursi M, Generali D, De Maria R, Risi E, Ciliberto G, Sperduti I, Villa A, Barba M, Di Leo A, Vici P.
Int J Cancer. 2019 Jul 22.

47. VALIDATION OF THE AJCC PROGNOSTIC STAGE FOR HER2-POSITIVE BREAST CANCER IN THE SHORTER TRIAL.

Dieci MV, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Giotta F, Aieta M, Gebbia V, Musolino A, Garrone O, Donadio M, Rimanti A, Beano A, Zamagni C, Soto Parra H, Piacentini F, Danese S, Ferro A, Cagossi K, Sarti S, Gambaro AR, Romito S, Bazan V, Amaducci L, Moretti G, Foschini MP, Balduzzi S, Vicini R, D'Amico R, Griguolo G, Guarneri V, Conte PF.
BMC Med. 2019 Nov 21;17(1):207. doi: 10.1186/s12916-019-1445-z

48. PREDICTIVE ROLE OF BODY COMPOSITION PARAMETERS IN OPERABLE BREAST CANCER PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY.

Omarini C, Palumbo P, Pecchi A, Draisci S, Balduzzi S, Nasso C, Barbolini M, Isca C, Bocconi A, Moscetti L, Galetti S, Tazzioli G, Torricelli P, Cascinu S, Piacentini F.
Cancer Manag Res. 2019 Nov 12;11:9563-9569

49. COMBINED ENDOCRINE APPROACHES VS ENDOCRINE THERAPY ALONE AS FIRST LINE TREATMENT IN ELDERLY PATIENTS WITH HORMONE RECEPTOR-POSITIVE, HER2 NEGATIVE, ADVANCED BREAST CANCER: TO PRESCRIBE FOR THE PATIENT OR THE PHYSICIAN? A META-ANALYSIS OF PHASE II AND III RANDOMIZED CLINICAL TRIALS

Claudia Omarini, Federico Piacentini, Isabella Sperduti, Monica Barbolini, Chrystel Isca, Angela Toss, Laura Cortesi, Elena Barbieri, Massimo Dominici, Luca Moscetti
BMC Cancer. 2020 May 13;20(1):418. doi: 10.1186/s12885-020-06933-y

50. CANCER TREATMENT DURING THE CORONAVIRUS DISEASE 2019 PANDEMIC: DO NOT POSTPONE, DO IT!

Claudia Omarini, Michela Maur, Gabriele Luppi, Franco Narni, Mario Luppi, Massimo Dominici, Giuseppe Longo, Federico Piacentini
Eur J Cancer. 2020 May 12;133:29-32

51. MODULATION OF MUTATIONAL LANDSCAPE IN HER2-POSITIVE BREAST CANCER AFTER NEOADJUVANT CHEMOTHERAPY.

Omarini C, Bettelli S, Manfredini S, Barbolini M, Isca C, Cortesi G, Maiorana A, Tazzioli G, Dominici M, Piacentini F. *Transl Oncol.* 2020 May 30;13(9):100794

52. HENOCH-SCHÖNLEIN PURPURA (HSP) IN A PATIENT ON ABEMACICLIB.

Omarini C, Molinaro E, Barbolini M, Dominici M, Piacentini F. *Breast.* 2020 Jun 2;52:132-133.

53. PIK3CA Mutation in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer: Association with Prognosis and Integration with PAM50 Subtype.

Guarneri V, Dieci MV, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Musolino A, Giotta F, Rimanti A, Garrone O, Bertone E, Cagossi K, Nanni O, Piacentini F, Orvieto E, Griguolo G, Curtarello M, Urso L, Paré L, Chic N, D'Amico R, Prat A, Conte P.

Clin Cancer Res. 2020 Aug 25. doi: 10.1158/1078-0432.CCR-20-1731. Online ahead of print.

54. A MULTIVARIABLE PROGNOSTIC SCORE TO GUIDE SYSTEMIC THERAPY IN EARLY-STAGE HER2-POSITIVE BREAST CANCER: A RETROSPECTIVE STUDY WITH AN EXTERNAL EVALUATION.

Prat A, Guarneri V, Paré L, Griguolo G, Pascual T, Dieci MV, Chic N, González-Farré B, Frassoldati A, Sanfeliu E, Cejalvo JM, Muñoz M, Bisagni G, Brasó-Maristany F, Urso L, Vidal M, Brandes AA, Adamo B, Musolino A, Miglietta F, Conte B, Oliveira M, Saura C, Pernas S, Alarcón J, Llombart-Cussac A, Cortés J, Manso L, López R, Ciruelos E, Schettini F, Villagrasa P, Carey LA, Perou CM, Piacentini F, D'Amico R, Tagliafico E, Parker JS, Conte P.

Lancet Oncol. 2020 Nov;21(11):1455-1464. doi: 10.1016/S1470-2045(20)30450-2. PubMed PMID: 33152285.

55. PHASE II STUDY OF ERIBULIN IN COMBINATION WITH GEMCITABINE FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER (ERIGE TRIAL). CLINICAL AND PHARMACOGENETIC RESULTS ON BEHALF OF THE GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC).

Pellegrino B, Cavanna L, Boggiani D, Zamagni C, Frassoldati A, Schirone A, Caldara A, Rocca A, Gori S, Piacentini F, Berardi R, Brandes AA, Foglietta J, Villa F, Todeschini R, Tognetto M, Naldi N, Bortesi B, Montemurro F, Ardizzoni A, Boni L, Musolino A.

ESMO Open. 2020 Dec 31;6(1):100019. doi: 10.1016/j.esmoop.2020.100019. [Epub ahead of print] PubMed PMID: 33399082.

56. THE GROWING SKYLINE OF ADVANCED HEPATOCELLULAR CARCINOMA TREATMENT: A REVIEW.

Schipilliti FM, Garajová I, Rovesti G, Balsano R, Piacentini F, Dominici M, Gelsomino F. *Pharmaceuticals (Basel).* 2021 Jan 8;14(1):43.

57. IMMUNE MICROENVIRONMENT AND INTRINSIC SUBTYPING IN HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE BREAST CANCER.

Griguolo G, Dieci MV, Paré L, Miglietta F, Generali DG, Frassoldati A, Cavanna L, Bisagni G, Piacentini F, Tagliafico E, Cagossi K, Ficarra G, Prat A, Conte P, Guarneri V.

NPJ Breast Cancer. 2021 Feb 12;7(1):12

59. INTERSTITIAL LUNG DISEASE IN ABEMACICLIB-TREATED PATIENTS DURING SARS-COV-2 PANDEMIC: A CASE SERIES.

Barbolini, Monica; Omarini, Claudia; Toss, Angela; Cortesi, Giulia; Fiorani, Claudia; Piombino, Claudia, Dominici Massimo and Piacentini Federico

In *CLINICS IN ONCOLOGY* - ISSN:2474-1663 vol. 5

60. TWO-MONTH STOP IN MAMMOGRAPHIC SCREENING SIGNIFICANTLY IMPACTS ON BREAST CANCER STAGE AT DIAGNOSIS AND UPFRONT TREATMENT IN THE COVID ERA.

Toss A, Isca C, Venturelli M, Nasso C, Ficarra G, Bellelli V, Armocida C, Barbieri E, Cortesi L, Moscetti L, Piacentini F, Omarini C, Andreotti A, Gambini A, Battista R, Dominici M, Tazzioli G.

ESMO Open. 2021 Feb 11;6(2):100055

61. THE ROLE OF EXOSOMES IN BREAST CANCER DIAGNOSIS.

Piombino C, Mastrolia I, Omarini C, Candini O, Dominici M, Piacentini F, Toss A.

Biomedicines. 2021 Mar 18;9(3):312

62. THE PROGNOSTIC ROLE OF EARLY SKELETAL MUSCLE MASS DEPLETION IN MULTIMODALITY MANAGEMENT OF PATIENTS WITH ADVANCED GASTRIC CANCER TREATED WITH FIRST LINE CHEMOTHERAPY: A PILOT EXPERIENCE FROM MODENA CANCER CENTER.

Rimini M, Pecchi A, Prampolini F, Bussei C, Salati M, Forni D, Martelli F, Valoriani F, Canino F, Bocconi A, Gelsomino F, Reverberi L, Benatti S, Piacentini F, Menozzi R, Dominici M, Luppi G, Spallanzani A.

J Clin Med. 2021 Apr 15;10(8):1705

63. TRASTUZUMAB-LAPATINIB AS NEOADJUVANT THERAPY FOR HER2-POSITIVE EARLY BREAST CANCER: SURVIVAL ANALYSES OF THE CHER-LOB TRIAL.

Guarneri V, Dieci MV, Griguolo G, Miglietta F, Girardi F, Bisagni G, Generali DG, Cagossi K, Sarti S, Frassoldati A, Gianni L, Cavanna L, Pinotti G, Musolino A, Piacentini F, Cinieri S, Prat A, Conte P; of the CHER-Lob study team.

Eur J Cancer. 2021 Aug;153:133-141

64. QUALITY OF LIFE OF THERAPIES FOR HORMONE RECEPTOR POSITIVE ADVANCED/METASTATIC BREAST CANCER: REGULATORY ASPECTS AND CLINICAL IMPACT IN EUROPE.

Moscetti L, Sperduti I, Frassoldati A, Musolino A, Nasso C, Toss A, Omarini C, Dominici M, Piacentini F.

Breast. 2021 Jul 12;59:232-238

65. DRUG-DRUG INTERACTIONS BETWEEN PALBOCICLIB AND PROTON PUMP INHIBITORS MAY SIGNIFICANTLY AFFECT CLINICAL OUTCOME OF METASTATIC BREAST CANCER PATIENTS.

Del Re M, Omarini C, Diodati L, Palleschi M, Meattini I, Crucitta S, Lorenzini G, Isca C, Fontana A, Livi L, Piacentini F, Fogli S, De Giorgi U, Danesi R.

ESMO Open. 2021 Sep 9;6(5):100231

66. CARCINOID CRISIS: A MISUNDERSTOOD AND UNRECOGNIZED ONCOLOGICAL EMERGENCY.

Bardasi C, Benatti S, Luppi G, Garajová I, Piacentini F, Dominici M, Gelsomino F.

Cancers (Basel). 2022 Jan 28;14(3):662

67. TRASTUZUMAB DERUXTECAN VERSUS TRASTUZUMAB EMTANSINE FOR BREAST CANCER.

Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators.

N Engl J Med. 2022 Mar 24;386(12):1143-1154.

68. OCULAR TOXICITY IN BREAST CANCER MANAGEMENT: MANUAL FOR THE ONCOLOGIST.

Canino F, Omarini C, Cerma K, Moscetti L, Tornincasa A, Trudu L, Dominici M, Piacentini F.

Clin Breast Cancer. 2022 Jun;22(4):289-299

69. T-DM1 EFFICACY IN TRASTUZUMAB-PERTUZUMAB PRE-TREATED HER2 POSITIVE METASTATIC BREAST CANCER PATIENTS: A META-ANALYSIS.

Omarini C, Piacentini F, Sperduti I, Cerma K, Barbolini M, Canino F, Nasso C, Isca C, Caggia F, Dominici M, Moscetti L.

BMC Cancer. 2022 Jun 7;22(1):623

70. ROLE OF INTRINSIC SUBTYPE ANALYSIS WITH PAM50 IN HORMONE RECEPTORS POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER: A SYSTEMATIC REVIEW.

Canino F, Piacentini F, Omarini C, Toss A, Barbolini M, Vici P, Dominici M, Moscetti L.

Int J Mol Sci. 2022 Jun 25;23(13):7079

71. COVID-RELATED DISRUPTION IN MAMMOGRAPHIC SCREENING: A YEAR LATER.

Toss A, Callegari V, Cortesi G, Civallero M, Armocida C, Piacentini F.

ESMO Open. 2022 Jul 13;7(4):10053

72. PROGNOSTIC SIGNIFICANCE OF GERMLINE BRCA MUTATIONS IN PATIENTS WITH HER2-POSITIVE BREAST CANCER.

Viansone A, Pellegrino B, Omarini C, Pistelli M, Boggiani D, Sikokis A, Uliana V, Zanoni D, Tommasi C, Bortesi B, Bonatti F, Piacentini F, Cortesi L, Camisa R, Sgargi P, Michiara M, Musolino A.

73. STATINS INCREASE PATHOLOGICAL RESPONSE IN LOCALLY ADVANCED RECTAL CANCER TREATED WITH CHEMORADIATION: A MULTICENTER EXPERIENCE.

Caputo F, Santini C, Casadei-Gardini A, Cerma K, Bardasi C, Garajová I, Lattanzi E, Passardi A, Rapposelli IG, Spallanzani A, Salati M, Bonetti LR, Gelmini R, Meduri B, Piccoli M, Pecchi A, Benatti S, Piacentini F, Dominici M, Luppi G, Gelsomino F.

74. PREDICTIVE FACTORS FOR RELAPSE IN TRIPLE-NEGATIVE BREAST CANCER PATIENTS WITHOUT PATHOLOGICAL COMPLETE RESPONSE AFTER NEOADJUVANT CHEMOTHERAPY.
Toss A, Venturelli M, Civallero M, Piombino C, Domati F, Ficarra G, Combi F, Cabitza E, Caggia F, Barbieri E, Barbolini M, Moscetti L, Omarini C, Piacentini F, Tazzioli G, Dominici M, Cortesi L.
Front Oncol. 2022
75. SUCCESSES AND FAILURES OF ANGIOGENESIS BLOCKADE IN GASTRIC AND GASTRO-ESOPHAGEAL JUNCTION ADENOCARCINOMA.
Salati M, Caputo F, Bocconi A, Cerri S, Baldessari C, Piacentini F, Dominici M, Gelsomino F.
Front Oncol. 2022
76. TARGETING PI3K/AKT/MTOR PATHWAY IN BREAST CANCER: FROM BIOLOGY TO CLINICAL CHALLENGES.
Cerma K, Piacentini F, Moscetti L, Barbolini M, Canino F, Tornincasa A, Caggia F, Cerri S, Molinaro A, Dominici M, Omarini C.
Biomedicines. 2023
77. PERSONALIZED SYSTEMIC THERAPIES IN HEREDITARY CANCER SYNDROMES.
Mastrodomenico L, Piombino C, Riccò B, Barbieri E, Venturelli M, Piacentini F, Dominici M, Cortesi L, Toss A.
Genes (Basel). 2023
78. CAPIVASERTIB IN HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER.
Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS; CAPitello-291 Study Group.
N Engl J Med. 2023
79. INCORPORATING WEEKLY CARBOPLATIN IN ANTHRACYCLINE AND PACLITAXEL-CONTAINING NEOADJUVANT CHEMOTHERAPY FOR TRIPLE-NEGATIVE BREAST CANCER: PROPENSITY-SCORE MATCHING ANALYSIS AND TIL EVALUATION.
Dieci MV, Carboognin L, Miglietta F, Canino F, Giorgi CA, Cumerlato E, Amato O, Massa D, Griguolo G, Genovesi E, Garufi G, Giannarelli D, Tornincasa A, Trudu L, Michieletto S, Saibene T, Lo Mele M, Fassan M, Zarrilli G, Piacentini F, Bria E, Guarneri V.
Br J Cancer. 2023
80. PATHOLOGIC RESPONSE AND SURVIVAL AFTER NEOADJUVANT CHEMOTHERAPY WITH OR WITHOUT PERTUZUMAB IN PATIENTS WITH HER2-POSITIVE BREAST CANCER: THE NEOPEARL NATIONWIDE COLLABORATIVE STUDY.
Fabbri A, Nelli F, Botticelli A, Giannarelli D, Marrucci E, Fiore C, Virtuoso A, Scagnoli S, Pisegna S, Alesini D, Sini V, Orlandi A, Fabi A, Piacentini F, Moscetti L, D'Auria G, Gamucci T, Mazzotta M, Pizzuti L, Vici P, Cretella E, Scavina P, La Cesa A, Persano M, Atzori F, Ruggeri EM.
Front Oncol. 2023
81. ADJUVANT ENDOCRINE THERAPY IN PREMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE EARLY-STAGE BREAST CANCER: RISK STRATIFICATION IN A REAL-WORLD SETTING.
D'Onofrio R, Omarini C, Toss A, Sperduti I, Piacentini F, Barbolini M, Cortesi L, Barbieri E, Pettorelli E, Chiavelli C, Dominici M, Moscetti L.
Clin Breast Cancer. 2023
82. METASTATIC SITE PATTERNS BY INTRINSIC SUBTYPE AND HER2DX IN EARLY HER2-POSITIVE BREAST CANCER.
Dieci MV, Conte P, Bisagni G, Bartolini S, Frassoldati A, Generali D, Piacentini F, Griguolo G, Tagliafico E, Brasó Maristany F, Chic N, Paré L, Miglietta F, Vicini R, D'Amico R, Balduzzi S, Prat A, Guarneri V.
J Natl Cancer Inst. 2024 Jan 10;116(1):69-80
83. NINE-WEEK VERSUS ONE-YEAR TRASTUZUMAB FOR EARLY HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE BREAST CANCER: 10-YEAR UPDATE OF THE SHORTER PHASE III RANDOMIZED TRIAL. Conte P, Bisagni G, Piacentini F, Sarti S, Minichillo S, Anselmi E, Aieta M, Gebbia V, Schirone A, Musolino A, Garrone O, Beano A, Rimanti A, Giotta F, Turletti A, Miglietta F, Dieci MV, Vicini R, Balduzzi S, D'Amico R, Guarneri V.
J Clin Oncol. 2023 Nov 10;41(32):4976-4981

84. THROMBOEMBOLISM AND ADJUVANT ENDOCRINE THERAPY (AET) IN HORMONE RECEPTOR-POSITIVE EARLY BREAST CANCER (EBC): DID TREATMENT EVOLUTION CHANGE INCIDENCE OF THE ADVERSE EVENT? A META-ANALYSIS. D'Onofrio R, Sperduti I, Piacentini F, Barbolini M, Omarini C, Toss A, Cortesi L, Barbieri E, Canino F, Dominici M, Moscetti L. *Clin Breast Cancer*. 2023 Dec;23(8):e534-e541.
85. REAL-WORLD DATA AND CLINICAL IMPLICATIONS OF NEXT-GENERATION SEQUENCING (NGS)-BASED ANALYSIS IN METASTATIC BREAST CANCER PATIENTS. Canino F, Tornincasa A, Bettelli S, Manfredini S, Barbolini M, Moscetti L, Omarini C, Toss A, Tamburrano F, Antonelli G, Baglio F, Belluzzi L, Martinelli G, Natalizio S, Ponzoni O, Dominici M, Piacentini F. *Int J Mol Sci*. 2024 Feb 20;25(5):2490
86. SAFETY AND EFFICACY ANALYSIS OF NEOADJUVANT PERTUZUMAB, TRASTUZUMAB AND STANDARD CHEMOTHERAPY FOR HER2-POSITIVE EARLY BREAST CANCER: REAL-WORLD DATA FROM NEOPOWER STUDY. Canino F, Barbolini M, De Giorgi U, Fontana T, Gaspari V, Gianni C, Gianni L, Maestri A, Minichillo S, Moscetti L, Mura A, Nicoletti SVL, Omarini C, Pagani R, Sarti S, Toss A, Zamagni C, Cuoghi Costantini R, Caggia F, Antonelli G, Baglio F, Belluzzi L, Martinelli G, Natalizio S, Ponzoni O, Dominici M, Piacentini F. *BMC Cancer*. 2024 Jun 15;24(1):735
87. TRASTUZUMAB DUOCARMAZINE IN PRETREATED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-POSITIVE ADVANCED OR METASTATIC BREAST CANCER: AN OPEN-LABEL, RANDOMIZED, PHASE III TRIAL (TULIP). Turner N, Saura C, Aftimos P, van den Tweel E, Oesterholt M, Koper N, Colleoni M, Kaczmarek E, Punie K, Song X, Armstrong A, Bianchi G, Stradella A, Ladoire S, Lim JSJ, Quenel-Tueux N, Tan TJ, Escrivá-de-Romani S, O'Shaughnessy J; TULIP Trial Investigators. *J Clin Oncol*. 2024 Oct 23;JCO2400529.
88. SPONTANEOUS REGRESSION OF AN INFLAMMATORY MYOFIBROBLASTIC TUMOR: A CASE REPORT AND A REVIEW OF THE LITERATURE. Medici B, Caffari E, Salati M, Spallanzani A, Garajova I, Piacentini F, Dominici M, Gelsomino F. *Case Rep Oncol*. 2024 Oct 22;17(1):1208-1213
89. DEVELOPMENT OF TWO MACHINE LEARNING MODELS TO PREDICT CONVERSION FROM PRIMARY HER2-0 BREAST CANCER TO HER2-LOW METASTASES: A PROOF-OF-CONCEPT STUDY F. Miglietta, A. Collesei, C. Vernieri, T. Giarratano, C. A. Giorgi, F. Girardi, G. Griguolo, M. Cacciatore, A. Botticelli, A. Vingiani, G. Fotia, F. Piacentini, D. Massa, F. Zanghi, M. Marino, G. Pruneri, M. Fassan, A. P. Dei Tos, M. V. Dieci & V. Guarneri *ESMO Open*. 2024 Dec 19;10(1):104087
90. AUTOMATE THE PROCESS OF FORMALIN-FIXED PARAFFIN-EMBEDDED BLOCKS STORAGE IN THE PATHOLOGY LABORATORY: A PROOF OF CONCEPT STUDY. Albino Eccher, Stefano Marletta, Fabio Pagni, Vincenzo L'Imperio, Federico Piacentini, Massimo Dominici, Alberto Cavazza, Carmine Pinto, Matteo Brunelli, Michelangelo Fiorentino, Umberto Malapelle, Marco Maria Baron, Guido Martignoni, Angelo Paolo Dei Tos *Pathol Res Pract*. 2024 Dec 26;266:155802


Book Chapters

- V. Guarneri, F Piacentini, PF Conte: Progress in the treatment of Early and Advanced Breast Cancer. In "Breast Cancer. Nuclear Medicine in Diagnosis and Therapeutic Options", a cura di E. Bombardieri, G Bonadonna, L Gianni, Springer edizioni
- F. Piacentini: Carcinosi peritoneale e carcinoma lobulare infiltrante della mammella <http://oncologia.recentiproggressi.it/ricerca.asp>
- PF. Conte, E. Barbieri, V. Guarneri, F. Piacentini, MV. Dieci: Tumori Ginecologici in "Oncologia Clinica – Principi e pratica – Volume 4", a cura di R. Cellerino, G. Cetto, A. Piga, CEA SELECTA MEDICA edizioni
- RISPOSTA RAPIDA E DURATURA A FULVESTRANT IN PAZIENTE CON MALATTIA METASTATICA E IMPEGNO VISCERALE
F. Piacentini in *Trattamento di prima linea con fulvestrant nel carcinoma della mammella metastatico – Anno XIII, n°8, agosto 2012*
- 5. OXFORD MANUALE DI MEDICINA CLINICA Edizione Italiana coordinata da Paolo Ventura – A cura di Chiara Cuoghi, Nicola De Ruvo, Matteo Marcacci, Federico Piacentini

Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae in base all'art. 13 del D.Lgs. 196/2003 e all'art. 13 del Regolamento UE 2016/679 (GDPR) ai fini stessi dell'accreditamento ECM e di tutte le procedure ad esso riconducibili.

MODENA, 16 March 2024

Dott. FEDERICO PIACENTINI

A handwritten signature in black ink, appearing to read 'F. Piacentini', with a stylized flourish at the end.